Abiraterone Acetate (AA) is an important agent in the treatment of advanced prostate cancer. It was primarily approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) after failure of androgen deprivation therapy.
There is still no available strong data regarding the impact of early decline of prostate-specific antigen (PSA) in the overall survival. The aim of this study was to evaluate the clinical efficacy of an early prostate-specific antigen response as a predictor of overall survival (OS) in metastatic castration-resistant prostate cancer when treated with Abiraterone Acetate.
A dual center, retrospective, cohort study on patients diagnosed with mCRPC treated with abiraterone between 2013 and 2020 was performed. Primary end-point was to demonstrate the efficacy of AA, with the analysis of PSA decline, and the correlation with overall survival.
The cohort analysis consisted of 84 patients with a median age of 71 ± 9 years. A PSA response of > 30% and > 50% at 60 and 90 days was associated with improved OS. Multivariate analysis revealed that a 60 day PSA decline of > 30% was predictive of overall survival. Median OS of diag-nosed mCRPC patients was 28 months. Docetaxel pre-treatment was not associated with longer OS. The median duration of drug exposure for patients submitted to AA was found to be 14 months.
Early PSA response rate can offer clinically meaningful information and can be considered a surrogate of longer OS. A > 30% or > 50% prostate-specific antigen decline at 60 and 90 days provided an important low-cost clinical tool to pre-dict subsequent events in mCRPC patients treated with abiraterone.
Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica. 2023 Feb 22 [Epub ahead of print]
Alexandre Mendonça Macedo, Rita Gameiro Marques, Margarida Cunha André, Nuno Silva Figueira, Miguel Leal Carvalho
Urology Department, Hospital Garcia de Orta EPE, Almada, Portugal; 2 Oncology Department, Centro Hospitalar Barreiro Montijo,. ., Oncology Department, Centro Hospitalar Barreiro Montijo, Barreiro. ., Urology Department, Hospital Garcia de Orta EPE, Almada. ., Urology Department, Hospital Garcia de Orta EPE, Almada. ., Urology Department, Hospital Garcia de Orta EPE, Almada. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/36924378